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Abstract
Background: Programmed Death Ligand 1 (PD-L1) is an immune modulating protein expressed on the surface of
various inflammatory cells, including T Cells, B Cells, dendritic cells, and macrophages. PD-L1 represents an
important diagnostic target; expression of PD-L1 on the surface of tumor cells, or within tumor-associated immune
cells, is an important predictor of likely response to targeted therapies. In this study, we describe the optimization
of immunohistochemistry (IHC) assays using two PD-L1 antibodies (SP263 and E1L3N) and compare the
performance of the optimized assays.
Methods: Fully automated immunohistochemical assays were optimized for the VENTANA PD-L1 (SP263) Rabbit
Monoclonal Antibody and the PD-L1 (E1L3N®) XP® Rabbit mAb using instruments and detection chemistries from
Ventana Medical Systems, Inc. (“SP263 assay” and “E1L3N assay,” respectively). Tissue microarrays (TMAs) containing
formalin fixed paraffin embedded (FFPE) non-small cell lung cancer (NSCLC) cases were used for the optimization
and comparison staining. H scores were used for membrane scoring whereas percent positivity was used for
tumor-associated immune cell scoring.
Results: One-hundred NSCLC TMA case cores each stained with the SP263 and E1L3N assays were evaluated by
two pathologists in a blinded study. Analysis of these specimens showed that the SP263 assay was more sensitive
and had a wider dynamic range than the E1L3N assay. For sensitivity, many cases were found to be negative for
membrane staining with the E1L3N assay, but had measurable staining with the SP263 assay. Dynamic range was
demonstrated by the SP263 assay having well-distributed H scores while the E1L3N assay had a significantly higher
proportion of cases clustered in the lowest H score bins. For tumor-associated immune cell staining, the two assays
identified similar amounts of cells staining in each case, but the SP263 assay gave overall darker staining.
Conclusion: Since PD-L1 status is important for targeted therapies, having a specific and accurate diagnostic test is
crucial for identifying patients who could benefit from these treatments. Due to its staining intensity, scoring range,
and pathologist preference, the SP263 IHC assay has been deemed superior to the E1L3N IHC assay. Future clinical
utility remains to be determined.
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Background
Tumor formation and persistence is a complex process
involving a number of different cellular and subcellular
aberrations that may or may not be mediated by abnor-
mal cell signaling events. The tumor microenvironment
plays a critical role not just in the formation of these
malignancies, but also the maintenance, spread, and sur-
vival of the neoplasms. Components of the microenvir-
onment that determine the stability of the tumor include
the tumor cells themselves, the vasculature, and the
tumor-associated immune cells. The tumor-associated
immune cells play a critical, yet poorly defined, role in
determining the survival or destruction of the tumor.
The role of the immune system in the formation,
maintenance, or destruction of cellular malignancies is
an emerging area of focus for cancer biologists and clini-
cians [1–5]. Although the concept itself is not new, the
mechanisms mediating these processes have yet to be
elucidated. Some components of the innate immune sys-
tem, including natural killer cells, have been implicated
in angiogenic events supporting tumor formation and
growth [6]. However, other components of the immune
system, including macrophages and lymphocytes, have
been associated with anti-tumorigenic activities targeting
these neoplasms [7, 8]. Furthermore, the type and extent
of the tumor-associated immune cells has been associ-
ated with variable clinical outcomes, and therefore cer-
tain immune-specific antigens can represent attractive
clinical and diagnostic targets [9].
Most therapies targeting immune modulating antigens
either promote an immune response, or inactivate
immune-inhibitory mechanisms. Proteins within a cer-
tain T Cell associated pathway, the PD-L1/PD-1 path-
way, tend to be commonly targeted. Programmed Death
Ligand 1 (PD-L1) is an immune modulating protein
expressed on the surface of various inflammatory cells,
including T Cells, B Cells, dendritic cells, and macro-
phages [10]. Overexpression of PD-L1 within normal in-
flammatory cells, as well as ectopic expression on the
surface of tumor cells, has been associated with tumor
persistence as a result of an ablated immune response
[11, 12]. Expression of PD-L1 on the surface of tumor
cells inactivates primed CD8+ T Cells by binding to its
high affinity receptor, PD-1. This immune inhibiting ef-
fect shuts down the machinery programmed to destroy
the tumor cells.
Several directed therapies targeting either the receptor
(PD-1) or its ligand (PD-L1) are in various phases of
clinical trials [13]. By binding to either PD-1 or PD-L1,
these monoclonal antibodies effectively prevent PD-L1-
induced activation of the PD-1 pathway, and shut down
the immune-inhibiting function of PD-L1. As a target of
therapy, PD-L1 represents an important diagnostic tar-
get; expression of PD-L1 within the tumor-associated
immune cells or on the surface of tumor cells is an im-
portant predictor of likely response to these targeted
therapies. Therefore, a diagnostic test that specifically
and accurately detects PD-L1, with sufficient analytic
sensitivity, is critically important in order to identify pa-
tients likely to benefit from these treatments.
Immunohistochemical tests are relatively inexpensive,
quickly performed, and widely accessible in most clinical
markets. Additionally, assaying for the protein itself pro-
vides direct diagnostic data that is more likely to corres-
pond to a clinical benefit than detecting non-therapeutic
targets, such as DNA or RNA. With a multitude of com-
mercially available antibodies and staining platforms
available, identifying a single clone and associated assay
is important in order to standardize the diagnostic mo-
dality used. This report describes the optimization and
comparison of two PD-L1 clones with respect to their
analytical performance and clinical applications.
Methods
Specimens
TMAs containing formalin fixed paraffin embedded
(FFPE) non-small cell lung cancer (NSCLC) cases
(LC1923) were procured from US Biomax, Inc. (Rock-
ville, MD, USA) and were used for optimizing the PD-L1
immunohistochemistry (IHC) assays and performing the
assay comparison staining. FFPE sections (4 μm) were
provided by the vendor on positively charged slides. A
board certified pathologist reviewed H&E stains of the
specimens and all were deemed acceptable for use.
PD-L1 antibody clones
Two anti-PD-L1 antibodies were examined, clones SP263
(Ventana Medical Systems, Tucson, AZ) and E1L3N (Cell
Signaling Technologies, Danvers, MA). The SP263 rabbit
monoclonal was generated with a synthetic peptide de-
rived from the C-terminus of human PD-L1 protein. The
E1L3N rabbit monoclonal was produced by immunizing
with a synthetic peptide corresponding to residues near
the C-terminus.
Automated PD-L1 immunohistochemistry staining pro-
cedure optimization
Immunohistochemical staining was carried out on the
VENTANA BenchMark ULTRA automated staining
platform using the OptiView detection kit (VMSI, Cata-
log No. 760–700). The manufacturer recommend dilu-
tion of the E1L3N clone for a manual overnight staining
protocol produced suboptimal staining quality on the
automated staining platform. Therefore, the E1L3N
clone was re-optimized for direct comparison to the
SP263 clone. During development and optimization of
the SP263 and E1L3N assays, antigen retrieval, primary
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antibody concentration, and primary antibody diluent
were examined.
Antigen retrieval was optimized by evaluating a variety
of cell conditioning buffers and incubation times. Ab-
sence of cell conditioning was investigated and deter-
mined to yield unacceptable staining. Cell conditioning 1
(CC1) buffer (VMSI, Catalog No. 950–224) is a TRIS
based buffer of alkaline pH. This was tested using a
32 min incubation both with and without Protease 3
(VMSI, Catalog No. 760–2020) for 4 min, and a 64 min
incubation of only CC1. Cell conditioning 2 (CC2) buffer
(VMSI, Catalog No. 950–223) is a citrate based buffer
with an acidic pH. This buffer was evaluated using a
32 min incubation time. Finally, a more potent enzym-
atic antigen retrieval reagent, Protease 1 (VMSI, Catalog
No. 760–2018), was evaluated for 4 min of incubation
time. Of these conditions, 64 min of CC1 at standard
temperature was superior to the other conditions tested
and was selected as the antigen retrieval parameter for
the final assays.
The intensity of staining at different concentrations of
the anti-PD-L1 antibodies was evaluated by the patholo-
gist to select the ideal titer. An automatically dispensed
concentration of each clone was selected based on the
pathologist’s interpretation of relevant positive staining
and non-specific background reactivity.
Finally, five diluents (VMSI proprietary) were screened
and evaluated to optimize staining quality. The choice of
diluent potentially impacts not only positive staining in-
tensity, but also background staining and antibody sta-
bility. The diluent that resulted in the most ideal signal
to noise ratio was selected for the final assay.
Both clones performed best with the same assay condi-
tions, although the optimal antibody concentrations dif-
fered (Table 1).
Final automated PD-L1 immunohistochemistry staining
procedures
Antigen recovery was conducted for 64 min with CC1
buffer. Slides were incubated with a dilution of the stock
primary antibodies in a dilution buffer for 16 min at 36 °
C. Stock antibody refers to the concentration at which
the antibody was provided to Ventana by the manufac-
turer. The SP263 assay was used at 1.25 μg/mL and the
E1L3N assay was used at 17.50 μg/mL in the final opti-
mized assays. As a negative reagent control, specimens
were incubated with a rabbit monoclonal negative con-
trol antibody under the same conditions.
The primary antibodies were detected using the Opti-
View detection kit. Enzymatic detection of anti-PD-L1
antibodies was accomplished with a secondary goat anti-
mouse and anti-rabbit IgG conjugated to HQ, followed
by an anti-HQ conjugated to HRP. Chromogen was de-
posited by a reaction with hydrogen peroxide in the
presence of diaminobenzidine (DAB) and copper sulfate.
The secondary antibody, HRP multimer, and all chromo-
gen reagents were applied at the instrument’s default
times.
Slide evaluation
Serial sections of a commercial TMA (LC1923) contain-
ing one hundred NSCLC cases were stained with the
SP263 and E1L3N assays. Two board certified patholo-
gists evaluated one hundred NSCLC cases. Interpret-
ation of stains included assessment of tumor cell
staining for membrane localization as well as percent
positivity of the tumor-associated immune cells. Stained
tissues were scored on a four point scale (0, 1, 2, and 3)
for membrane tumor staining. Dark brown membrane
staining was scored a 3, moderate brown membrane
staining a 2, and light tan to brown membrane staining
intensity a 1 (no membrane staining was scored a 0).
The percentage of cells staining positively at each inten-
sity level was recorded. In tumor samples, only viable
malignant cells were scored.
H scores, which combine components of staining in-
tensity with the percentage of positive cells, were calcu-
lated. H scores have a value ranging from 0 to 300 and
are defined as:
1 * (percentage of cells staining at 1+ intensity)
+2 * (percentage of cells staining at 2+ intensity)
+3 * (percentage of cells staining at 3+ intensity)
= H score.
Tumor-associated immune cell staining was measured
as percent positive cells infiltrating the tumor at any in-
tensity of stain.
Table 1 Description of Anti-PD-L1 Antibodies and Assay Conditions Examined










SP263 Spring Rabbit 1.25 μg/mL Benchmark
Ultra
OptiView 64' CC1 0.05 M Tris-HCI with 1 % carrier protein,
and 0.10 % ProClin 300, a preservative
16'/36 °C 4'/4'
E1L3N CST Rabbit 17.50 μg/mL Benchmark
Ultra
OptiView 64' CC1 0.05 M Tris buffered saline, 0.01 M EDTA,
0.05 % Brij-35 with 0.3 % carrier protein
and 0.05 % sodium azide, a preservative
16'/36 °C 4'/4'
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During evaluation, the pathologists were blinded to
the assays performed on each array.
The two pathologists independently participated in a
survey to assess the qualitative performance of each
assay. Questions were answered on a scale of 1 to 10,
with 1 being very much disliked and 10 being very much
liked. Areas assessed included ease of interpreting mem-
brane staining in the tumor and in the tumor-associated
immune cells, the ability to distinguish tumor staining
from tumor-associated immune cell staining, and signal
to noise ratio. The survey also focused on overall assay
aesthetic preference and the ability of the assay to serve
as a companion diagnostic in a clinical setting. The re-
sults from the survey are summarized in Table 2.
Slide imaging
Images of stained slides were captured on the Aperio
ScanScope® XT system. Slides were scanned at 20X and
the resulting images were used for photomicrographs.
Data analysis
Data analyses were performed using standard available
functions in Excel. The scientists performing the data
analyses were blinded to the identity of the assays until
all analysis was completed.
Assay specificity for the SP263 and E1L3N assays was
determined by noting cell types stained and the subcel-
lular localization of the stain. Assay sensitivity and
range were examined by comparing calculated H
scores. Concordance between assays (inter-assay) and
concordance between pathologists (inter-pathology)
were evaluated. Inter-assay correlation was gauged by
comparing a single pathologist’s H scores for mem-
brane staining in the tumor along with the percent
positivity of the tumor-associated immune cells for the
SP263 and E1L3N PD-L1 assays. Inter-pathologist cor-
relation was determined by comparing each patholo-
gist’s H scores for membrane staining in the tumor
along with the percent positivity of the tumor-associated
immune cells for the same PD-L1 assay. Tumor-associated
immune cell staining was analyzed by comparing the per-
centages of cells that stained for each assay.
The pathologists’ qualitative assay survey results were
quantified using the numerical answers given to each




The Spring Bioscience anti-PD-L1 antibody clone SP263
and the CST anti-PD-L1 antibody clone E1L3N were op-
timized for use in a fully automated immunohistochemi-
cal assay on the VENTANA BenchMark ULTRA
staining platform with the OptiView DAB IHC Detec-
tion Kit. The assay was optimized for detection of PD-
L1 expression in non-small cell lung cancer (NSCLC).
Parameters evaluated included antibody concentration,
antibody diluent, cell conditioning time and buffer, and
antibody incubation time and temperature. The opti-
mized assay conditions for each antibody were identical,
with the exception of the optimal antibody concentra-
tion (Table 1).
Qualitative assay evaluation
NSCLC specimens stained with the SP263 and E1L3N
assays were evaluated by two pathologists in a blinded
study. Staining was evaluated on a 1–10 scale for quality
of PD-L1 membrane staining in the tumor, as well as for
PD-L1 staining in the tumor-associated immune cells.
The ease of quantifying both the staining itself and the
percentage of positive cells were evaluated, as was the
signal to noise ratio, and overall assay aesthetics. The re-
sults are summarized in Table 2.
The SP263 assay received significantly higher scores
from the pathologists for identification of membrane
staining, as well as for ease of quantifying the percentage
of positive tumor cells with membrane staining and the
percentage of positive tumor-associated immune cells.
The E1L3N assay was deemed unacceptable for ease of
quantifying the percent of positive staining in tumor cell
membranes and in the tumor-associated immune cells.
Table 2 PD-L1 Pathology Evaluation Survey and Results
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Although both assays stained similar numbers of inflam-
matory cells, the darker staining of the SP263 assay
allowed for easier quantification (Fig. 1). The SP263
assay received a significantly higher score for signal to
noise ratio than the E1L3N assay, indicating that it was
cleaner, with specific staining more easily differentiated
from any non-specific background staining (Table 2).
Both assays received similar scores for overall aesthetic
preference, with the SP263 assay slightly preferred.
Assay specificity
The specificity of each assay was assessed by observing
the types of cells staining in the NSCLC cases and by
observing the subcellular localization of the staining and
comparing with previously published reports. Both as-
says stained the cytoplasm and membrane of tumor cells
(Fig. 1b, c) as well as cells in the tumor-associated im-
mune cells (Fig. 1e, f ), consistent with previous reports
[14, 15]. As expected, non-neoplastic cells were negative
for PD-L1 staining with both assays, yielding good signal
to noise ratios.
Assay sensitivity
Analysis of the one hundred NSCLC cores found that
the SP263 assay was more sensitive than the E1L3N
assay. Twenty-nine cases found to be negative for mem-
brane staining by the E1L3N assay were found to have
measurable anti-PD-L1 staining with the SP263 assay
(Additional file 1: Table S1). In all twenty-four cases
positive by both assays, the SP263 assay yielded higher
H scores for membrane anti-PD-L1 staining.
When the membrane H scores for each case are plot-
ted against each other on a scatter plot the slope of the
best fit line is greater than 1 (Fig. 2a), indicating a higher
sensitivity for the SP263 assay. This trend was seen by
both evaluating pathologists. Scatter plots of the percent
of tumor cells with membrane staining identified by
each assay indicate that the SP263 assay identifies more
positive cells than the E1L3N assay, particularly at the
lower intensity levels (Fig. 2b). Since H scores are a
product of both the percentage of cells staining and the
intensity at which the cells stain, and the SP263 assay
identifies more cells staining at greater intensity, the H
scores tend to be higher for the SP263 assay than the
E1L3N assay on the same cases. This can be seen by
examination photomicrographs of cases stained with
each assay (Fig. 1b, c).
Assay range
Analysis of the one hundred NSCLC cores also found
that the SP263 assay had a wider dynamic range than
the E1L3N assay. Tumor membrane H scores were
binned using increments of 25, and the percentage of
cases in each bin was used to generate histograms
(Fig. 3a). Membrane H score distribution for the SP263
assay ranged from the 0 bin to the 300 bin, whereas the
membrane H scores for the same samples with the
E1L3N assay ranged from the 0 bin to the 200 bin.
Fig. 1 Immunohistochemical Staining of PD-L1 on NSCLC a H&E of NSCLC case D4 (20X magnification). b SP263 Assay demonstrating membrane
and cytoplasm staining of tumor cells (20X magnification). c E1L3N Assay demonstrating membrane and cytoplasm staining of tumor cells (20X
magnification). d H&E of NSCLC case A15 (20X magnification). e SP263 Assay demonstrating staining of tumor-associated immune cells
(20X magnification). f E1L3N Assay demonstrating staining of tumor-associated immune cells (20X magnification)
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Fig. 2 Analysis of PD-L1 Assay Sensitivity a Scatter plots comparing membrane H scores for each assay from pathologist 1 and 2. b Scatter plots
of the percent of tumor cells with membrane staining for each assay from pathologist 1 and 2
Fig. 3 Analysis of PD-L1 Assay Range of Tumor Area a Histograms of tumor membrane H scores, binned from 0 to 300 in increments of 25, and
the percentage of cases in each of the bins from pathologist 1 and 2. b A table showing how each assay was represented across membrane H
score bins from pathologist 1 and 2
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While the SP263 assay had well-distributed scores, the
E1L3N assay had a significantly higher proportion of
cases clustered in the lowest scoring bins. In addition,
the SP263 assay had cases fall into a larger number of
bins than the E1L3N assay (Fig. 3b). These observations
were consistent between the two pathologists.
For tumor-associated immune cell staining, the SP263
and E1L3N assays had similar ranges (Fig. 4, Additional
file 2: Table S2). Both assays typically had staining in 0–
10 % of the immune infiltrate, with only a single case for
each assay staining a higher percentage. Although the
two assays identified similar amounts of cells staining in
each case, the SP263 assay gave an overall darker stain-
ing (Fig. 1e, f ). This allowed for easier quantification of
staining in the tumor-associated immune cells using the
SP263 assay, and contributed to the pathologists’ prefer-
ence for this assay.
Inter-pathologist correlation
To determine the level of inter-pathologist correlation
when scoring each assay, the individual pathologists’ H
scores for membrane staining in the tumor and percent
positive cells in the tumor-associated immune cells were
compared. Both the SP263 assay (R2 > 0.87) and the
E1L3N assay (R2 > 0.82) had high inter-pathologist cor-
relation for membrane tumor staining scores (Fig. 5a).
The range of scores for the E1L3N assay is significantly
compressed relative to the SP263 assay. These results in-
dicate that the tumor cell staining generated by both
assays can be scored reproducibly by different patholo-
gists, with the SP263 assay producing the more concord-
ant results. Both assays had lower inter-pathologist
correlation (SP263 R2 > 0.66, E1L3N R2 > 0.80) for per-
cent of positively staining cells in the immune infiltrate
(Fig. 5b). The E1L3N assay had stronger inter-pathologist
correlation, but had almost twice as many cases with no
staining as compared to the SP263 assay (Additional file 2:
Table S2).
Discussion
Recent studies have linked PD-L1 expression in tumors
with response to immunotherapies targeting PD-L1 or
its receptor PD-1 [15–18]. These findings highlight the
necessity of a specific, robust, fully-automated PD-L1
IHC assay to be used in patient selection for clinical tri-
als and to identify additional tumor types that may bene-
fit from targeted PD-L1/PD-1 immunotherapy.
Fully automated immunohistochemical assays were
optimized for the VENTANA PD-L1 (SP263) Rabbit
Monoclonal Antibody and the PD-L1 (E1L3N®) XP®
Rabbit mAb using instruments and detection chemistries
from Ventana Medical Systems, Inc. (“SP263 assay” and
“E1L3N assay,” respectively). Both assays stained PD-L1
in the tumor membrane and cytoplasm, and also in the
tumor-associated immune cells, consistent with previous
results with other PD-L1 clones [14, 15]. The tumor
areas stained and subcellular localization pattern within
tumor cells was consistent across both assays. Both
assays demonstrated high signal to noise ratio, and stain-
ing was not observed in normal lung tissue or in cancer-
adjacent stromal regions. Taken together these data
suggest that both the SP263 and E1L3N assays are
highly specific for PD-L1. Both assays also generated
scores in the tumor cell membrane that were highly
reproducible from pathologist to pathologist, a charac-
teristic required for future use as a diagnostic assay.
Pathologist to pathologist correlation for percent posi-
tive tumor-associated immune cells was lower for both
assays, indicating that consistent scoring of the percent
positivity in the tumor-associated immune cells is more
difficult than H scoring of tumor cells. Low percent
positivity means that small changes in estimated per-
cent staining can have a large effect on the correlation
of the data.
Although both assays stained with a similar pattern
and stained similar percentages of tumor cells and
tumor-associated immune cells, the SP263 assay was
highly preferred by both pathologists when blinded to
Fig. 4 Analysis of PD-L1 Assay Range of Tumor-Associated Immune Cells Scatter plots comparing percent staining of tumor-associated immune
cells for each assay from pathologist 1 and 2
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the identity of each assay in the qualitative survey. The
SP263 assay yielded significantly darker staining in the
tumor cells and tumor-associated immune cells com-
pared to the E1L3N assay. The difference in staining in-
tensity allowed for easier quantification of the staining
in the tumor membrane and for easier quantification of
percentage of cells staining in the tumor-associated im-
mune cells for the SP263 assay. The average H score for
the membrane tumor cell staining was higher for the
SP263 assay in all cases that were positive by both as-
says, and the SP263 assay generated a much larger range
of scores than the E1L3N assay, which was clustered to-
wards the low end of the scoring range. In addition, PD-
L1 staining was detected by the SP263 in many NSCLC
cases that were negative by the E1L3N assay, suggesting
that the SP263 assay has higher sensitivity. The overall
weaker staining using the E1L3N assay likely contributes
to a higher likelihood of false negatives, especially in
cases where only focal staining is present.
Definitions of PD-L1 positivity vary from study to
study and from cancer type to cancer type, and include
different thresholds of expression in either tumor cells
and/or the tumor-associated immune cells [15–17, 19,
20]. The ideal IHC assay for detection of PD-L1 expres-
sion should allow for a wide range of scores in both
tumor cells and tumor-associated immune cells; using
future clinical outcome data the threshold of PD-L1
clinical positivity could be further refined. Based on its
staining characteristics, the SP263 assay is superior for
detecting PD-L1 expression in both tumor cells and
tumor-associated immune cells, and is promising for use
as both a diagnostic tool and a means of patient stratifi-
cation for immunotherapy. The clinical utility of this
assay needs to be verified in clinical studies.
Conclusions
In conclusion, the SP263 assay is superior for detecting
expression of PD-L1 in tumor cells and/or tumor-
associated immune cells, when compared to the E1L3N
assay. The SP263 assay not only demonstrated darker
staining intensity in tumor cells and tumor-associated
immune cells, but also generated a greater scoring range
which suggests higher sensitivity. The blinded board-
certified pathologists who scored the assay expressed, in
their qualitative survey, a preference for the SP263 assay.
Since PD-L1 status is important for targeted therapies,
having a specific and accurate diagnostic test is crucial
for identifying patients who could benefit from these
treatments. Although SP263 is an analytically superior
assay to the others tested, evaluating its predictive claim
to any specific therapy can only be accomplished during
the course of a controlled clinical trial.
Fig. 5 Inter-pathologist Correlation of PD-L1 Assays (a) Scatter plots comparing membrane H scores for each assay from pathologist 1 and 2. b
Scatter plots comparing percent positivity in tumor-associated immune cells for each assay from pathologist 1 and 2
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Additional file 1: Average Membrane H Scores for 100 NSCLC Cases
Stained with the SP263 Assay and the E1L3N Assay. (PPTX 86 kb)
Additional file 2: Average Percent Positive Tumor-Associated Immune
Cells for 100 NSCLC Cases Stained with the SP263 Assay and the E1L3N
Assay. (PPTX 97 kb)
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